United Therapeutics Co. (NASDAQ:UTHR) Shares Bought by Daiwa Securities Group Inc.

Daiwa Securities Group Inc. increased its stake in United Therapeutics Co. (NASDAQ:UTHR) by 26.1% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,119 shares of the biotechnology company’s stock after purchasing an additional 852 shares during the period. Daiwa Securities Group Inc.’s holdings in United Therapeutics were worth $1,476,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the stock. Cerity Partners LLC boosted its stake in United Therapeutics by 82.1% in the 3rd quarter. Cerity Partners LLC now owns 8,886 shares of the biotechnology company’s stock worth $3,184,000 after purchasing an additional 4,005 shares in the last quarter. Pacer Advisors Inc. boosted its stake in United Therapeutics by 0.9% in the 3rd quarter. Pacer Advisors Inc. now owns 566,703 shares of the biotechnology company’s stock worth $203,078,000 after purchasing an additional 4,869 shares in the last quarter. Cypress Capital Group purchased a new position in United Therapeutics during the 3rd quarter worth approximately $212,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its position in United Therapeutics by 64.4% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 32,092 shares of the biotechnology company’s stock worth $11,500,000 after buying an additional 12,566 shares during the last quarter. Finally, Premier Fund Managers Ltd purchased a new position in United Therapeutics during the 3rd quarter worth approximately $5,307,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Christopher Causey sold 510 shares of the business’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $376.63, for a total transaction of $192,081.30. Following the transaction, the director now owns 3,675 shares of the company’s stock, valued at approximately $1,384,115.25. The trade was a 12.19 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO James Edgemond sold 7,785 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the transaction, the chief financial officer now directly owns 2,615 shares in the company, valued at approximately $947,597.55. The trade was a 74.86 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 127,227 shares of company stock valued at $47,398,820 in the last 90 days. 11.90% of the stock is owned by insiders.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $378.13 on Friday. The firm has a market cap of $16.88 billion, a PE ratio of 16.61, a PEG ratio of 1.07 and a beta of 0.56. The firm has a fifty day moving average of $366.89 and a 200 day moving average of $334.15. United Therapeutics Co. has a one year low of $208.62 and a one year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $748.90 million for the quarter, compared to analysts’ expectations of $722.62 million. During the same quarter in the previous year, the company posted $5.38 EPS. The firm’s quarterly revenue was up 22.9% on a year-over-year basis. On average, equities analysts predict that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Argus raised their price target on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. TD Cowen raised their price target on shares of United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. HC Wainwright raised their price target on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Bank of America reduced their price target on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research report on Thursday, August 1st. Finally, LADENBURG THALM/SH SH raised their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $370.86.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.